Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-3: belantamab mafodotin versus pomalidomide + low-dose dexamethasone in relapsed/refractory multiple myeloma
NL-OMON52689Phase 3Recruiting
- Sponsor
- GSK
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Belantamab mafodotin with Pomalidomide + low-dose dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Dec 2020; status: recruiting.
02
Drugs
belantamab mafodotinpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON52689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52689.